Oncoinvent (ONCIN)

[Jeppsi]

Jeg overtegnet 66% i rep-emien. Siden kursen har ligget stabilt et godt stykke over tegningskursen på 2 kr i hele rep-emi perioden, blir det spennende å se om det blir noe «til overs» utover tegningsrettene.

[InVivo]

Lovende uttalelser fra industrien. Backer opp uttalelsen til Øystein Soug før jul

Fortune and Insight base some of their growth projections on the surge in clinical trials underway for investigational radiopharma drugs, an increase that is likely to fuel more M&A activity, according to Matt Furlow, Ph.D., an associate principal at management consulting and technology firm ZS.

“We’ll start to see acquisition or licensing activity driven by clinical data inflection points,” Furlow said in an interview. “If we see a big data release, even early phase clinical trials from one of these companies that is still independent, that’ll certainly drive interest in larger companies that have yet to enter this space.”

[Tixis]

Vil d kunne sees på vps om man har fått noe i morgen?

[Jeppsi]

Det står følgende på VPS:

Regner med «Offentlig tildeling» sier når tildelingsprosessen er ferdig. Mulig det tar litt tid før man ser resultatet i VPS, men forhåpentligvis ila 07.02

[TekBot]

Oncoinvent ASA: Final results of the subsequent offering and allocation of offer shares

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 6 February 2025
…

Vis børsmeldingen

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (the “Subsequent Offering”), as well as the stock exchange announcement from earlier today, regarding today being the last day of the subscription period in the Subsequent Offering.

The subscription period in the Subsequent Offering expired today, on 6 February 2025 at 12:30 hours (CET). The final results show that the Company has received valid subscriptions for a total of 11,075,035 Offer Shares. As 5,500,000 Offer Shares were offered under the Subsequent Offering, the Subsequent Offering was accordingly oversubscribed.

Notifications of allocated Offer Shares in the Subsequent Offering and the corresponding amount to be paid by each subscriber will be set out in a separate allocation notification to each subscriber. The allocation notifications are expected to be available through the Norwegian Central Securities Depository tomorrow, on 7 February 2025. The deadline for payment for the Offer Shares is 11 February 2025, in accordance with the payment instructions set out in the Company’s information document that is available at the Managers’ (as defined below) websites: Ongoing prospectuses and offerings: - Carnegie Norway and www.dnb.no/emisjoner.

The Offer Shares may not be transferred or traded until they are fully paid and the share capital increase pertaining to the Subsequent Offering has been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). The Company will by a stock exchange announcement announce when the share capital increase has been registered.

Subject to timely payment of the Offer Shares subscribed for and allocated in the Subsequent Offering, the issuance and delivery of the Offer Shares pertaining to the Subsequent Offering is expected to be completed on or about 18 February 2025. The Managers (as defined below) may be contacted for information regarding allocation, payment and delivery of the Offer Shares.

Following the issuance of the 5,500,000 Offer Shares, the Company’s share capital will be NOK 9,774,334.30, divided into 97,743,343 shares, each with a nominal value of NOK 0.10.

Advisors:
Carnegie AS and DNB Markets, a part of DNB Bank ASA are acting as managers in the Subsequent Offering (the “Managers”).
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company. Advokatfirmaet Wiersholm AS is acting as legal advisor to the Managers.

Further information about the Subsequent Offering is included in the information document.
The information in this announcement is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.
This stock exchange announcement was published by Tore Kvam, CFO of the Company on 6 February 2025 20:05 CET on behalf of the Company.

About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com

Important information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “US Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act.

The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States.

This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any Member State.

The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company providing the protections afforded to their respective clients or for providing advice in relation to the Subsequent Offering and/or any other matter referred to in this release.

Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[TyrionIV]

@TekBot

The final results show that the Company has received valid subscriptions for a total of 11,075,035 Offer Shares. As 5,500,000 Offer Shares were offered under the Subsequent Offering, the Subsequent Offering was accordingly oversubscribed.

Godt overtegna ihvertfall!

[Jeppsi]

Ser tildelingen for rep-emien er inne i VPS nå (Hendelser → Tildelinger).

Juhuu, jeg fikk de 66% ekstra jeg overtegnet. Kan tyde på at det var mange uten tegningsretter som også søkte.

[hybrid]

Tror selskapet har prioritert eksisterende aksjonærer som gjerne ikke var klar over at emisjonen ble utvidet i første omgang(som da gjorde at de i utgangspunktet ikke fikk retter i rep.emi), jeg tegnet uten retter og fikk det jeg ønsket.

Hadde vært interessant å se hvem som ville ha de 5mill ekstra aksjene

[pensjonist]

Jeg tegnet også ekstra, og fikk alle!

Jeg satt opp et konto.nr når jeg tegnet, blir pengene automatisk trukket fra den kontoen, eller må jeg føre manuelt over?

[InVivo]

Da blir vel neste event dataslipp i q2 og q3.

Kommer data inn på linje med det vi har sett så langt så har jo Soug uttalt at de håper på å lande en partneravtale i løpet av 2025. Skulle de klare å få en avtale som tar vekk behovet for flere emisjoner, så er blue sky estimatet mitt på 200-400 kr aksjen fortsatt oppnåelig, gitt gode data.

I det finansieringsrisikoen forsvinner, så kan aksjen stige raskt mot 10-20 kr

[Boms]

Hadde selv bare en liten post fra før, tegnet 5 x antall retter og fikk alt.

Tipper det har vært ett fåtall uten retter som har tegnet mye, og at de har strøket disse. Eventuelt så har en av hovedeierne tegnet mye for å sikre at det ble fulltegnet, også har de blitt strøket når det var nok interesse ellers.

[Merlin]

Kraftig overtegning, rart kursen faller i dag?

[hybrid]

Egentlig ikke,

Har ligget noe gratis penger der, og når tildelinger ble offentliggjort så er det vel noen som har vært litt opportunistiske da.

[Tixis]

Jeg hadde ikke aksjer den dagen man måtte ha det for å få i emisjon. Tegnet meg for 10k. Fikk ikke det, men fikk faktisk litt uten å ha rett på det.
Da blir d for meg å kjøpe i markedet i tiden fremover. Vil nok være noe som kommer ut på mandag da emi aksjene skal være mulig å handle. Alltid noen som vil ta en kjapp 20%

[hybrid]

Blir fort sånn når man(du) tegner 10mill aksjer av 5,5mill mulige, Merlin.

[urban66]

• Oncoinvent har fullført den etterfølgende emisjonen (subsequent offering)
• Det ble tilbudt 5,5 millioner nye aksjer til kurs 2 NOK per aksje
• Emisjonen ble overtegnet med totalt 11.075.035 aksjer tegnet
• Tildeling av aksjer vil bli tilgjengelig via VPS 7. februar 2025
• Betalingsfrist er satt til 11. februar 2025
• Forventet levering av de nye aksjene er rundt 18. februar 2025.

Du må nok vente til tirsdag 18. Forøvrig virker dette som en lotteripreget emisjon. Fikk 100% av de jeg søkte, og økte stacken med 80%. Så ikke den komme, og måtte selge halvparten i dag for å betale mandag. Men klønete av meg å ikke tro/håpe det beste, og holde 80K. klar til sikkert siste bunnfisketrålet for Oncoinvent . Uansett alt i alt meget fornøyd med dagensendelikt

[Oilimp]

Du hadde vel ca 45 millioner kr i Nano, så da får vi håpe du tar igjen tapet derfra

[pensjonist]

Vet du om pengene trekkes automatisk i morgen (på den kontoen man oppga under bestilling), eller må man overføre noe manuelt?

[urban66]

Trekkes automatisk.

[Tixis]

Var det 18 feb emisjonsaksjene ble tilgjengelig i markedet? Altså at de som fikk i emisjon har anledning til å selge disse?
Jeg er trukket på konto men ser ikke aksjene på aks ennå.
Mener jeg har sett datoen 18 feb et sted men finner d ikke igjen